Trump administration sides with OpenAI in lawsuit against New York Times

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-09-02 • Permanent link

Fears of a global economic downturn have resurfaced after the latest trial of Ultragenyx's experimental treatment for Angelman syndrome, a rare genetic disorder, failed to show significant results. The phase III trial, conducted in collaboration with the National Institutes of Health, involved 40 patients and was designed to assess the efficacy of the treatment. The trial's disappointing outcome has sent shockwaves through the biotech industry, with investors and analysts scrambling to reassess their expectations.

Rumors of a volatile bond market have been circulating for weeks, and yesterday's 2.5% jump in the City of London's benchmark bond index only fueled the fire. Investors are growing increasingly anxious about the market's unpredictable nature, with some experts warning of a potential crisis. The jump in bond yields has also raised concerns about the impact on mortgage rates and the broader economy.

The latest development in the ongoing debate over AI and intellectual property rights has its roots in the 1980s, when the first AI systems were first developed. Since then, the field has grown exponentially, with companies like Google and Microsoft investing heavily in AI research and development. However, the question of how to regulate AI and ensure fair compensation for creators has remained a contentious issue.

The Trump administration's decision to side with OpenAI in its lawsuit against the New York Times has significant implications for the tech industry and beyond. The move could set a precedent for the use of AI in journalism, with some experts warning that it could lead to a loss of editorial independence. As the debate over AI and intellectual property rights continues to simmer, investors and consumers will be watching closely for any further developments.